ZymoGenetics' Doug Williams discusses his next big step in biotech; No advisory meeting for Endo;

 @FierceBiotech: Dear Henri: Sanofi chief advises Genzyme against defensive moves. Report | Follow @FierceBiotech

 @JohnCFierce: Skin into blood, without the stem cell step? Story | Follow @JohnCFierce

> Departing ZymoGenetics CEO Doug Williams tells Xconomy: "I sort of feel that after 20-plus years in the business, I'm starting to figure out some of the do's and don'ts. I'm definitely not ready to stop. I enjoy working in this business. It's a real gift to be able to work around a bunch of smart people and do things that are ultimately good, in the sense we develop important drugs." Q&A

> The FDA says it no longer needs a meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to review Endo's New Drug Application for the new oral formulation of long-acting oxymorphone. Endo release

> Merck has pulled its European app for a combo asthma therapy, citing regulatory issues. Story

> Snowdon has been awarded a new three-year contract worth up to $8.2 million in development support from the Defense Department for the discovery and preclinical development of novel medical treatments to combat biowarfare pathogens. Snowdon release

And Finally... According to a new study, a minute change in a particular gene is associated with a significantly higher willingness to donate. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.